| |
original article |
Date |
Title |
Authors All Authors |
| 1 |
[GO] |
2023―Mar―29 |
Characteristics of hypervirulent multi-drug resistant Klebsiella pneumoniae strains in inpatients with severe COVID-19 |
A.E. Goncharov, D.V. Azarov, A.S. Mokhov, A.A. Pochtovyi, D.D. Kustova, V.A. Gushchin, et al. (+9) E.A. Lebedeva, V.V. Kolodzhieva, A.G. Kireeva, L.A. Kraeva, S.V. Dolinny, O.A. Burgasova, A.R. Goncharova, E.I. Belkova, A.V. Dmitriev |
| 2 |
[GO] |
2023―Mar―29 |
Defects in the interferon system associated with a deficiency of natural killers and T-cells in patients with COVID-19 |
I.V. Nesterova, V.N. Gorodin, G.A. Chudilova, V.N. Chapurina, V.A. Matushkina, L.V. Lomtatidze, et al. (+4) Т.А. Semenenko, V.V. Malinovskaya, A.N. Shuvalov, E.N. Vyzhlova |
| 3 |
[GO] |
2023―Mar―29 |
Pathomorphological changes in some organs and tissues of COVID-19 convalescent patients |
V.G. Akimkin, O.S. Levin, A.A. Ploskireva, A.V. Gorelov, A.G. Komarova, A.S. Litvinenko, et al. (+2) N.M. Krivosheeva, I.O. Tinkova |
| 4 |
[GO] |
2023―Mar―29 |
Efficacy and safety of imidazolyl ethanamide pentandioic acid for COVID-19: a multicenter, randomized, double-blind, placebo-controlled clinical trial |
A.V. Gorelov, A.G. Malyavin, E.A. Antonova, T.A. Pobedinskaya, А.А. Globenko, A.V. Kapashin, M.I. Bagaeva |
| 5 |
[GO] |
2022―Apr―15 |
Effects of recombinant IFN-α2b on the phenotype of neutrophil granulocyte subpopulations in patients with COVID-19 |
I.V. Nesterova, V.N. Gorodin, G.A.Chudilova Chudilova, V.N. Chapurina, V.A. Matushkina, R.Yu. Gabdrakhmanova, et al. (+4) L.V. Lomtatidze, S.V. Kovaleva, V.V. V.V.Malinovskaya, Т.А. Semenenko |
| 6 |
[GO] |
2022―Apr―15 |
Experience in the use of biological therapy (tocilizumab) in children with severe forms of COVID-19 |
L.N. Mazankova, I.M. Osmanov, E.R. Samitova, M.A. Antsupova, I.I. Afukov, A.B. Malakhov, et al. (+3) N.V. Loban, N.A. Dracheva, A.A. Volter |
| 7 |
[GO] |
2022―Apr―15 |
Results of RT-PCR test for the presence of SARS-CoV-2 in multiple organs of post-COVID patients who died from causes other than COVID-19 |
S.S. Petrikov, M.A. Godkov, A.A. Kanibolotsky, N.S. Dyakun, A.K. Shabanov, V.V. Kulabukhov, et al. (+2) A.T. Leinsoo, A.I. Bazhenov |
| 8 |
[GO] |
2022―Apr―15 |
Rationale for antiepidemic measures aimed to prevent focal incidence of COVID-19 in dormitories (on the example of Moscow) |
A.V. Zadoroshnyy, N.Yu. Pshenichnaya, V.G. Akimkin, V.V. Maleev |
| 9 |
[GO] |
2022―Apr―08 |
Therapeutic potential of inosine pranobex in enhancing non-specific antiviral protection in patients with COVID-19 |
D.V. Isakov |
| 10 |
[GO] |
2022―Apr―08 |
Clinical and laboratory characteristics COVID-19 |
D.A. Shikhnebiev, R.M. Ragimov, Z.G. Tagirova, N.M. Abdullaeva, A.E. Muslimova |
| 11 |
[GO] |
2022―Apr―08 |
Serotonin adipate in intensive therapy of patients with severe COVID-19 |
M.V. Bykov, D.V. Chernyshyov, E.N. Lazareva, S.V. Krasnova, N.A. Tsvetkova, Zh.B. Ponezheva, et al. (+2) V.G. Akimkin, V.V. Maleev |
| 12 |
[GO] |
2022―Apr―08 |
Clinical and epidemiological significance of diarrhea in children with COVID-19 |
L.N. Mazankovа, S.G. Gorbunov, E.R. Samitova, I.M. Osmanov, V.G. Akimkin, A.A. Ploskireva, et al. (+2) А.N. Os’kin, A.A. Mishkin |
| 13 |
[GO] |
2022―Apr―08 |
Efficacy of recombinant interferon α-2b in the complex therapy of COVID-19 |
V.V. Krasnov, A.A. Katirkina, P.G. Zubarov, A.A. Levina, G.S. Bragina, E.N. Vyzhlova |
| 14 |
[GO] |
2022―Apr―08 |
Proactive anti-inflammatory therapy with levilimab for patients with COVID-19 |
V.N. Gorodin, D.L. Moisova, S.V. Zotov, A.A. Vanyukov, Yu.E. Сhumakova |
| 15 |
[GO] |
2022―Apr―08 |
COVID-19 as many-faced Janus. On the classification of a new coronavirus infection |
A.V. Gorelov, A.A. Ploskireva, Zh.B. Ponezheva, Kh.G. Omarova, S.V. Nikolaeva, A.R. Marzhokhova, et al. (+6) E.R. Samitova, A.D. Muzyka, A.V. Lukyanov, A.A. Mishkin, N.M. Krivosheeva, I.A. Demina |
| 16 |
[GO] |
2022―Apr―08 |
Clinical and immunological characteristics of COVID-19 associated with human herpesvirus infections: management algorithms for mixed infections |
G.Kh. Vikulov, I.V. Oradovskaya |
| 17 |
[GO] |
2022―Apr―08 |
COVID-19 pandemic: a new round of antibiotic resistance |
V.G. Akimkin, A.V. Tutelyan, N.I. Shulakova, E.M. Voronin |
| 18 |
[GO] |
2022―Apr―08 |
Factors associated with poor outcomes in pneumonia patients during the COVID-19 pandemics |
A.Yu. Popova, E.B. Ezhlova, Yu.V. Demina, O.E. Trotsenko, A.P. Bondarenko, T.A. Zaitseva, et al. (+5) O.P. Kurganova, N.Yu. Pshenichnaya, E.A. Bazykina, T.N. Karavyanskaya, Yu.A. Natykan |
| 19 |
[GO] |
2022―Apr―08 |
Current concept of cerebral dysfunction in COVID-19 patients |
V.V. Maleev, S.M. Vedinov, V.N. Gorodin |
| 20 |
[GO] |
2022―Apr―08 |
Persistent hiccups as a new chief complaint of patients with COVID-19: A series of four cases |
Iraj Shahramian, Hadi Mirzaie, Morteza Salarzaei, Fateme Parooie |
| 21 |
[GO] |
2022―Apr―08 |
Resolution of the Council of Experts. New possibilities of etiotropic therapy for coronavirus infection |
|
| 22 |
[GO] |
2022―Apr―08 |
Hyperechogenic signal from the pericardium after vaccination against SARS-CoV-2 |
Z.N. Sukmarova, Yu.V. Ovchinnikov, G.O. Gudima, F.M. Ibragimova, O.V. Afonina, K.E. Machkalyan |
| 23 |
[GO] |
2022―Apr―08 |
Effect of azoximer bromide on the severity of clinical manifestations in patients after SARS-CoV-2 infection |
K. Kasyanenko, O.V. Maltsev, K.V. Kozlov, K.V. Zhdanov, I.F. Seryi |
| 24 |
[GO] |
2022―Apr―08 |
Characteristics of patients with severe and extremely severe SARS-CoV-2 infection treated in the intensive care unit of Nalchik Hospital No 1 |
A.R. Marzhokhova, A.A. Ploskireva, Z.F. Kharaeva, M.Yu. Marzhokhova, L.E. Balagova, M.R. Ivanova, et al. (+2) Z.A. Shomakhova, Zh.Yu. Pazova |
| 25 |
[GO] |
2021―Sep―16 |
Clinical and laboratory profile of patients with COVID-19 admitted to hospital in Moscow between May and July 2020 |
L.V. Kolobukhina, O.A. Burgasova, L.A. Kraeva, V.A. Gushchin, E.I. Burtseva, I.S. Kruzhkova, et al. (+17) I.N. Khlopova, L.N. Merkulova, K.G. Krasnoslobodtsev, N.A. Kuznetsova, E.V. Shidlovskaya, D.A. Dvorkina, V.B. Tetova, V.V. Bakalin, M.A. Odnoralov, L.V. Generalova, A.R. Khayrullina, N.A. Antipyat, A.V. Shagaev, O.E. Ambrosi, E.I. Kelli, E.E. Ushakova, S.V. Smetanina |
| 26 |
[GO] |
2021―Sep―16 |
Role of polymorphisms of genes involved in hemostasis in COVID-19 pathogenesis |
V.N. Gorodin, D.L. Moysova, S.V. Zotov, A.A. Vanyukov, A.A. Podsadnyaya, Yu.V. Tikhonenko |
| 27 |
[GO] |
2021―Sep―16 |
The use of interferon alpha-2b for prevention of novel coronavirus infection in healthcare workers |
Yu.O. Khlynina, A.A. Arova, A.B. Nevinsky |
| 28 |
[GO] |
2021―Jul―27 |
The lung-gut axis and COVID-19 |
V.P. Novikova, A.I. Khavkin, A.V. Polunina, A.V. Gorelov |
| 29 |
[GO] |
2021―Jul―27 |
Role of antioxidant therapy in patients with moderate and severe COVID-19 |
E.K. Shavarova, E.R. Cazakhmedov, M.V. Alekseeva, L.G. Ezhova, Zh.D. Kobalava |
| 30 |
[GO] |
2021―Jul―27 |
Combined oral contraceptives and treatment of new coronavirus infection (COVID-19): aspects of drug interactions |
O.A. Limanova, L.E. Fedotova, O.A. Gromova |
| 31 |
[GO] |
2021―Jul―27 |
Mono- and mixed respiratory tract infections in children: relevance of the problem during the COVID-19 pandemics |
S.V. Nikolaeva, D.V. Usenko, S.V. Shabalina, Yu.N. Khlypovka, A.V. Gorelov |
| 32 |
[GO] |
2021―Jul―23 |
Interferon alpha-2b in comprehensive treatment of patients with COVID-19 |
A.V. Mordyk, O.G. Ivanova, K.Yu. Samsonov, S.V. Sitnikova, L.A. Zenkova |
| 33 |
[GO] |
2021―Jul―23 |
The efficacy of intranasal recombinant interferon alpha-2b for emergency prevention of COVID-19 in healthcare workers |
I.V. Feldblium, M.Yu. Devyatkov, A.A. Gendler, S.M. Maltseva, T.M. Repin, V.N. Nikolenko |
| 34 |
[GO] |
2021―Jul―23 |
Epidemic process of COVID-19 in the Russian Federation: interim results. 2nd report |
N.Yu. Pshenichnaya, I.A. Lizinfeld, G.Yu. Zhuravlev, A.A. Ploskireva, V.G. Akimkin, A.A. Erovichenkov |
| 35 |
[GO] |
2021―Mar―10 |
The structure of seroprevalence to the SARS-CoV-2 virus among residents of the Moscow Region during the period of epidemic incidence of COVID-19 |
A.Yu. Popova, E.B. Ezhlova, A.A. Melnikova, O.M. Mikailova, S.Yu. Kombarova, M.A. Kostina, et al. (+20) A.V. Aleshkin, L.V. Lyalina, V.S. Smirnov, K.R. Gvazava, A.V. Kozlov, E.V. Chapov, D.A. Sychev, N.V. Khattatova, A.A. Basov, A.M. Zatevalov, L.I. Novikova, S.S. Bochkareva, E.I. Likhanskaya, A.A. Sharova, V.I. Lomonosova, A.A. Totolyan, S.Yu. Pchelintsev, A.V. Stepanov, G.A. Dmitriev, N.I. Leontievа |
| 36 |
[GO] |
2021―Mar―10 |
Collective immunity to SARS-CoV-2 of Moscow residents during the COVID-19 epidemic period |
A.Yu. Popova, E.B. Yezhlova, A.A. Melnikova, E.E. Andreeva, S.Yu. Kombarova, L.V. Lyalina, et al. (+18) V.S. Smirnov, A.V. Aleshkin, Yu.V. Kobzeva, E.N. Ignatova, M.N. Osadchaya, E.V. Nazarenko, L.N. Antipova, A.A. Basov, A.M. Zatevalov, L.I. Novikova, S.S. Bochkareva, E.I. Likhanskaya, V.I. Lomonosova, A.A. Totolian, N.M. Gracheva, E.A. Shmeleva, B.M. Manuilov, A.G. Lyutov |
| 37 |
[GO] |
2021―Mar―10 |
Socioeconomic aspects of COVID-19 on the example of Rostov region |
T.I. Tverdokhlebova, E.V. Kovalev, H.V. Karpushchenko, M.A. Kulak, O.S. Dumbadze, A.R. Litovko, A.S. Kaljuzhin |
| 38 |
[GO] |
2021―Mar―10 |
Evaluation of the preventive efficacy of recombinant interferon α-2b in ambulance personnel contacting with COVID-19 patients |
V.P. Vavilova, A.M. Vavilov, N.K. Perevoshchikova, S.A. Tsarkova |
| 39 |
[GO] |
2021―Mar―10 |
Meglumin acridonacetate to treat COVID-19: prospect of using |
P.V. Mazin, R.Kh. Khafisyanova, N.K. Mazina, A.L. Kovalenko, A.R. Askhadullin |
| 40 |
[GO] |
2020―Dec―17 |
Characteristics of COVID-19 and possibilities of early causal therapy. Results of favipiravir use in clinical practice |
L.A. Balykova, A.V. Govorov, A.O. Vasilyev, E.N. Simakina, A.S. Agafyina, A.Yu. Ivanova, et al. (+4) K.Ya. Zaslavskaya, M.V. Granovskaya, K.B. Kolontarev, D.Yu. Pushkar |
| 41 |
[GO] |
2020―Dec―17 |
Сoronavirus infection COVID-19 in children in the Russian Federation |
A.V. Gorelov, S.V. Nikolaeva, V.G. Akimkin |
| 42 |
[GO] |
2020―Dec―17 |
Some epidemiological aspects of the new coronavirus infection (COVID-19) in Rostov region |
A.R. Litovko, T.I. Tverdokhlebova, E.V. Kovalev, G.V. Karpushchenko, S.A. Nenadskaya, V.V. Agafonova, et al. (+8) A.A. Ryndich, A.G. Suladze, D.S. Kolpakov, N.N. Dolgova, N.V. Aleksanina, A.V. Aleshukina, G.S. Aleshukin, V.V. Denisenko |
| 43 |
[GO] |
2020―Dec―17 |
Epidemic process of COVID-19 in the Russian Federation: interim results. 1th report |
N.Yu. Pshenichnaya, I.A. Lizinfeld, G.Yu. Zhuravlev, А.A. Ploskireva, V.G. Akimkin |
| 44 |
[GO] |
2020―Dec―17 |
Recombinant interferons in comprehensive therapy for new coronavirus infection |
E.V. Melekhina, S.V. Nikolaeva, A.S. Ilyinskaya, Zh.B. Ponezheva, A.S. Akopyan, A.I. Krapivkin, et al. (+2) A.A. Korsunskiy, A.V. Gorelov |
| 45 |
[GO] |
2020―Oct―19 |
Antioxidants/antihypoxants: the missing puzzle piece in effective pathogenetic therapy for COVID-19 |
T.A. Voronina |
| 46 |
[GO] |
2020―Oct―19 |
Use of antiseptics in respiratory infections during the COVID-19 pandemic |
G.Kh. Vikulov |
|
